InterCure (NASDAQ:INCR – Get Free Report) and Tilray Brands (NASDAQ:TLRY – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.
Analyst Recommendations
This is a breakdown of recent recommendations for InterCure and Tilray Brands, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InterCure | 1 | 0 | 0 | 0 | 1.00 |
| Tilray Brands | 1 | 3 | 2 | 1 | 2.43 |
Tilray Brands has a consensus price target of $7.00, suggesting a potential upside of 69.49%. Given Tilray Brands’ stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than InterCure.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| InterCure | N/A | N/A | N/A |
| Tilray Brands | -13.11% | -7.76% | -5.59% |
Earnings and Valuation
This table compares InterCure and Tilray Brands”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InterCure | $78.47 million | 0.73 | -$10.37 million | $0.15 | 34.73 |
| Tilray Brands | $210.48 million | 2.67 | -$121.40 million | ($1.08) | -3.82 |
InterCure has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
8.3% of InterCure shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 0.8% of Tilray Brands shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
InterCure has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.
Summary
Tilray Brands beats InterCure on 9 of the 15 factors compared between the two stocks.
About InterCure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
About Tilray Brands
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.
Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.
